GSK says median overall survival not reached in multiple myeloma study

GSK (GSK) announced “statistically significant and clinically meaningful” overall survival results from a planned interim analysis of the DREAMM-7 trial evaluating belantamab mafodotin in combination with bortezomib plus dexamethasone versus daratumumab in combination with bortezomib plus dexamethasone as a second line or later treatment for relapsed or refractory multiple myeloma. With a median follow up of 39.4 months, the analysis shows a statistically significant 42% reduction in the risk of death among patients receiving the belantamab mafodotin combination versus the daratumumab-based comparator, the company said in a statement). Although the median overall survival was not reached in either arm of the study, the projected median overall survival for bortezomib plus dexamethasone is 84 months compared to 51 months for bortezomib plus dexamethasone, it added. The three-year overall survival rate was 74% in the belantamab mafodotin combination arm and 60% in the daratumumab combination arm. The survival benefit favoring bortezomib plus dexamethasone was seen as early as four months and was sustained over time, according to GSK.